Annual report
3151.TEDINET S100YDSN
Period2025-04-01 → 2026-03-31
Filed2026-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥610.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥600.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥587.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥578.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.0bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥5.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥7.8bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.6bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.5bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.4bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥7.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥7.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥320.6bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥299.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥317.3bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥297.3bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥313.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥201.9bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥192.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥118.7bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥107.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.9bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥100.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.0bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥19.4bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥23.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥4.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥8.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥3.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥152.29 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.02 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.03 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,423.12 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,193.96 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,085.09 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,911.44 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,858.86 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.6% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,871 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 3,756 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,705 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 3,719 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 3,754 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥5.6bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥4.8bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥4.7bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥7.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.1bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥74.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥75.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥76.1bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥18.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥21.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥56.2bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥54.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥48.3bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥46.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥97.03 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.93 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.33 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.57 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,162.56 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,123.29 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,039.86 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.75 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥868.78 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 75.1% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.5% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 51,902,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,902,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,902,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 52 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 54 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥13.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥13.8bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥12.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥35m |
| Medicine Wholesalereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| Medicine Wholesalereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| Medicine Wholesalereportable segment | employees | at 2026-03-31 | 2509 pure |
| Medicine Wholesalereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥583.9bn |
| Medicine Wholesalereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥572.9bn |
| Medicine Wholesalereportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥11.0bn |
| Medicine Wholesalereportable segment | segment assets | at 2026-03-31 | ¥298.9bn |
| Medicine Wholesalereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.9bn |
| Nursing Care Related Rental And Other Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥144m |
| Nursing Care Related Rental And Other Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥274m |
| Nursing Care Related Rental And Other Businessreportable segment | employees | at 2026-03-31 | 697 pure |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥7.9bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥5.0bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment assets | at 2026-03-31 | ¥16.1bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥102m |
| Pharmaceutical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥15m |
| Pharmaceutical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥0 |
| Pharmaceutical Businessreportable segment | employees | at 2026-03-31 | 3 pure |
| Pharmaceutical Businessreportable segment | segment assets | at 2026-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.3bn |
| Pharmacy Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥252m |
| Pharmacy Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥183m |
| Pharmacy Businessreportable segment | employees | at 2026-03-31 | 546 pure |
| Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥20.0bn |
| Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥20.0bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2026-03-31 | ¥9.3bn |
| Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥252m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥37m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥20m |
| Veterinary Drugs Wholesale Businessreportable segment | employees | at 2026-03-31 | 116 pure |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥12.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥12.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥6.1bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥304m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥6.5bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥3.9bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥624.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥610.5bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥13.8bn |
| —segment total | segment assets | at 2026-03-31 | ¥332.7bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Medicine Wholesalereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Medicine Wholesalereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medicine Wholesalereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥575.4bn |
| Medicine Wholesalereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥564.6bn |
| Medicine Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.8bn |
| Medicine Wholesalereportable segment | segment assets | at 2025-03-31 | ¥279.4bn |
| Medicine Wholesalereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥120m |
| Nursing Care Related Rental And Other Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥248m |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment assets | at 2025-03-31 | ¥12.8bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥78m |
| Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥88m |
| Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥157m |
| Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥9.4bn |
| Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥251m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥18m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥5.8bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥613.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥600.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13.5bn |
| —segment total | segment assets | at 2025-03-31 | ¥307.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Medicine Wholesalereportable segment | employees | at 2026-03-31 | 52 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,128
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row13Member | Original text (Japanese)住友ファーマ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row13Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row13Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row14Member | Original text (Japanese)協和キリン㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row14Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row14Member | Original text (Japanese)無 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row15Member | Original text (Japanese)デンカ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row15Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row15Member | Original text (Japanese)無 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row16Member | Original text (Japanese)日本新薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row16Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row16Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row17Member | Original text (Japanese)明治ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row17Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row17Member | Original text (Japanese)無 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)鳥居薬品㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row18Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)無 | |
| Footnotes deemed holdings of shares held for purposes other than pure investment second largest holding company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes deemed holdings of shares held for purposes other than pure investment second largest holding company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)㈱バイタルネット | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)㈱ケーエスケー | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)㈱オオノ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)㈱グッドネイバー | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | Original text (Japanese)㈱健康堂薬局 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | Original text (Japanese)㈱アグロジャパン | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | Original text (Japanese)㈱医療経営研究所 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row8Member | Original text (Japanese)㈱バイタルグリーン | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row9Member | Original text (Japanese)㈱バイタルケア | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row10Member | Original text (Japanese)㈱たんぽぽ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | Original text (Japanese)㈱バイタルエクスプレス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | Original text (Japanese)大伸通商㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | Original text (Japanese)㈱プレアーク | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | Original text (Japanese)㈲天王保健調剤センター | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | Original text (Japanese)アローメディカル㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row16Member | Original text (Japanese)共和運送㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row17Member | Original text (Japanese)㈱メドリープファーマ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row18Member | Original text (Japanese)八千代ケアサポート㈱ | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |